Sionna Therapeutics, Inc. (NASDAQ:SION) Receives $50.57 Consensus PT from Brokerages

Shares of Sionna Therapeutics, Inc. (NASDAQ:SION) have earned an average rating of “Moderate Buy” from the ten ratings firms that are covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, six have given a buy rating and two have issued a strong buy rating on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $50.5714.

Several brokerages have commented on SION. Raymond James Financial restated a “strong-buy” rating and issued a $53.00 price objective on shares of Sionna Therapeutics in a report on Monday, January 5th. BTIG Research restated a “buy” rating and issued a $58.00 price objective on shares of Sionna Therapeutics in a report on Monday, March 2nd. UBS Group restated a “buy” rating on shares of Sionna Therapeutics in a report on Monday, March 2nd. Weiss Ratings restated a “sell (e+)” rating on shares of Sionna Therapeutics in a report on Monday, December 29th. Finally, Citizens Jmp began coverage on shares of Sionna Therapeutics in a report on Tuesday, February 24th. They issued a “market outperform” rating and a $63.00 price objective for the company.

Sionna Therapeutics Stock Up 3.4%

NASDAQ:SION opened at $43.20 on Thursday. The company has a fifty day moving average of $38.07 and a 200 day moving average of $38.66. Sionna Therapeutics has a 52 week low of $10.97 and a 52 week high of $46.46. The firm has a market capitalization of $1.94 billion, a P/E ratio of -22.15 and a beta of 3.01.

Sionna Therapeutics (NASDAQ:SION) last posted its quarterly earnings results on Monday, March 2nd. The company reported ($0.46) EPS for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.15. As a group, analysts anticipate that Sionna Therapeutics will post -2.44 EPS for the current year.

Insider Buying and Selling at Sionna Therapeutics

In other Sionna Therapeutics news, Director Orbimed Advisors Llc sold 235,863 shares of the company’s stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $44.64, for a total value of $10,528,924.32. Following the completion of the transaction, the director directly owned 3,247,025 shares in the company, valued at approximately $144,947,196. This represents a 6.77% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter A. Thompson sold 235,863 shares of the company’s stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $44.64, for a total transaction of $10,528,924.32. Following the completion of the transaction, the director owned 3,247,025 shares of the company’s stock, valued at $144,947,196. This trade represents a 6.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,193,762 shares of company stock valued at $53,594,505 over the last 90 days. Company insiders own 3.90% of the company’s stock.

Institutional Trading of Sionna Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. TD Asset Management Inc grew its position in shares of Sionna Therapeutics by 74.3% in the 3rd quarter. TD Asset Management Inc now owns 87,082 shares of the company’s stock worth $2,561,000 after buying an additional 37,116 shares during the period. BNP Paribas Financial Markets purchased a new stake in shares of Sionna Therapeutics in the 2nd quarter worth about $31,000. Artia Global Partners LP purchased a new stake in shares of Sionna Therapeutics in the 4th quarter worth about $4,926,000. Eventide Asset Management LLC purchased a new stake in shares of Sionna Therapeutics in the 4th quarter worth about $26,290,000. Finally, ProShare Advisors LLC purchased a new stake in shares of Sionna Therapeutics in the 4th quarter worth about $202,000.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.